Summary: UnitedHealthcare modified its Medicare Advantage coverage policy for skin substitute grafts and cellular and tissue-based products (CTPs) delivered via injection and/or application, effective June 2, 2026. Here's what billing teams need to do.
UnitedHealthcare — the full official name for the payer operating under the UHC brand — updated this Medicare Advantage medical policy governing skin substitutes billing. The policy does not list specific CPT or HCPCS codes in the available data. Billing teams should treat this as a signal to audit their current charge capture and prior authorization workflows against UHC's updated criteria before the June 2, 2026 effective date.
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare (UHC) |
| Policy | Skin Substitutes Grafts/Cellular and Tissue-Based Products (Injections and/or Applications) – Medicare Advantage Medical Policy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-06-02 |
| Impact Level | High |
| Specialties Affected | Wound care, podiatry, plastic surgery, dermatology, general surgery, vascular surgery |
| Key Action | Audit all active skin substitute and CTP claims against updated medical necessity criteria before June 2, 2026 |
UnitedHealthcare Skin Substitute and CTP Coverage Criteria and Medical Necessity Requirements 2026
Skin substitutes and cellular and tissue-based products are one of the highest-scrutiny categories in wound care billing. UnitedHealthcare's coverage policy for these products has always been strict. This modification signals that UHC is tightening or clarifying the criteria again — which is consistent with the broader CMS and Medicare Advantage trend of reducing what payers consider routine reimbursement for these products.
The core issue is medical necessity. For any skin substitute graft or CTP injection and/or application to qualify for coverage under this UHC Medicare Advantage coverage policy, the clinical record must document that conservative wound care has failed. That typically means weeks of standard wound care — debridement, offloading, moisture management, infection control — with documented wound measurements showing inadequate healing progression.
UHC's Medicare Advantage plans follow CMS coverage principles as a baseline, but they can add restrictions. That's the key difference between Medicare fee-for-service and Medicare Advantage. Your patient may have Medicare, but if they're enrolled in a UHC Medicare Advantage plan, the UnitedHealthcare skin substitute coverage policy governs — not the local coverage determination (LCD) from your Medicare Administrative Contractor.
Prior authorization is almost certainly required for these products under UHC Medicare Advantage. This category has carried prior auth requirements for years across most major payers, and nothing in the policy change suggests that requirement is being relaxed. Before scheduling any application, confirm prior auth status. A missing or expired prior authorization is the fastest path to a claim denial on high-cost CTP products.
The "injections and/or applications" framing in the policy title matters. UHC is treating injected CTPs and topically applied skin substitutes under the same policy umbrella. Some older billing workflows treated these as separate billing pathways. If your team bills injected amniotic products differently from sheet-form skin substitutes, review how this unified policy applies to each product type you use.
UnitedHealthcare Skin Substitute and CTP Exclusions and Non-Covered Indications
Skin substitute billing has a long history of payer pushback on products that lack strong clinical evidence. UHC's Medicare Advantage policies consistently exclude products the payer considers experimental, investigational, or not medically necessary given the wound type.
Expect non-coverage for wounds that have not undergone an adequate trial of conservative therapy. If the record doesn't show prior standard of care treatment — and the specific duration UHC requires — the claim will deny. This isn't a technicality. It's the core of how UHC evaluates medical necessity for CTPs.
Products applied to wounds that are actively infected, poorly vascularized, or otherwise not meeting application-site criteria are also routinely excluded. The clinical documentation must support that the wound bed was adequately prepared before any CTP application. Applying a product to a wound that isn't ready doesn't just fail clinically — it fails the coverage criteria.
UHC also scrutinizes repeat applications. A single application with documented healing progression is easier to defend than multiple sequential applications. If your patients require more than one application, your documentation needs to show wound measurements at each visit, along with the clinical rationale for continuing CTP therapy versus escalating to a different treatment.
The real issue here is that "experimental or investigational" designations can shift with each policy update. If UHC reclassified any specific product category in this June 2026 modification, your billing team needs the line-by-line policy diff to catch it. A product that was covered under the prior version may not be covered under the updated version — and the change may not be obvious from the policy title alone.
Coverage Indications at a Glance
Because the available policy data does not include a granular indication list with associated codes, the table below reflects the standard coverage framework UHC applies to skin substitute and CTP policies under Medicare Advantage. Confirm these against the full policy document before the June 2, 2026 effective date.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Chronic wound with documented failure of conservative care | Covered (when criteria met) | Not listed in available data | Prior auth required; wound measurement documentation mandatory |
| Diabetic foot ulcer meeting depth/duration criteria | Covered (when criteria met) | Not listed in available data | Must document offloading compliance and infection control |
| Venous leg ulcer with compression therapy failure | Covered (when criteria met) | Not listed in available data | Compression therapy trial duration must be documented |
| Pressure injury/wound meeting clinical criteria | Covered (when criteria met) | Not listed in available data | Staging and conservative care documentation required |
| Wounds without prior conservative care trial | Not Covered | Not listed in available data | Medical necessity not met |
| Actively infected wound at time of application | Not Covered | Not listed in available data | Wound bed preparation required |
| Products classified as experimental or investigational | Not Covered | Not listed in available data | Product-specific; verify against updated policy version |
| Repeat applications without documented healing progression | Not Covered / Disputed | Not listed in available data | Requires wound measurements at each application visit |
This table reflects standard UHC Medicare Advantage criteria for CTPs. The policy data provided does not include a specific code list. Verify all indications against the full published policy document.
UnitedHealthcare Skin Substitute Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the full policy document before June 2, 2026. The available summary for this policy change does not include specific codes or a detailed criteria list. Get the complete published policy from UHC's provider portal. Read it against your current billing workflows line by line. |
| 2 | Audit your prior authorization process for every CTP product you use. Prior authorization for skin substitutes and CTPs under UHC Medicare Advantage is not optional. Confirm that your team is requesting auth before scheduling applications — not after. One missed prior auth on a high-cost graft product can cost thousands in denied reimbursement. |
| 3 | Update your clinical documentation templates to reflect UHC's medical necessity criteria. Your wound care notes must document the conservative care trial, wound measurements at each visit, healing progression (or lack thereof), and the clinical rationale for CTP use. Generic wound care notes don't clear UHC's medical necessity threshold. |
| 4 | Identify every UHC Medicare Advantage patient in your active wound care caseload. This policy change affects Medicare Advantage — not fee-for-service Medicare. Your billing team needs to flag patients by plan type before June 2. Run a payer mix report segmented by plan type if you haven't already. |
| 5 | Review your charge capture for injected CTPs separately from applied skin substitutes. The policy covers both injection and application routes under one umbrella. If your charge capture treats these differently, reconcile that against the updated policy. Misaligned billing pathways are a claim denial waiting to happen. |
| 6 | Talk to your compliance officer if you bill high volumes of CTPs. Skin substitute billing has been a target for Medicare Advantage audits and pre-payment review. A policy modification in this category is a signal that UHC is paying attention. If your practice does significant CTP volume, loop in your compliance officer before the effective date of June 2, 2026. |
| 7 | Watch for product-specific coverage changes. The policy title doesn't specify which products were affected by this modification. A line-by-line diff of the old versus new policy language will show you exactly what changed. Without that, you're guessing — and in skin substitute billing, guessing costs money. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Skin Substitute Grafts and CTPs Under UHC Medicare Advantage Policy
The policy data available for this UnitedHealthcare skin substitutes coverage policy modification does not include a specific list of CPT, HCPCS Level II, or ICD-10-CM codes. PayerPolicy does not fabricate or estimate codes.
This is significant. Skin substitute billing typically involves a large code set — including HCPCS Q-codes for specific graft products, CPT codes for application procedures, and ICD-10 diagnosis codes for wound types. The absence of a code list in the available data means you cannot assume which codes are affected by this modification without reviewing the full policy document directly.
What to Do
Pull the complete policy from UHC's provider portal. Cross-reference the code list against your current charge master and any superbills used by your wound care or surgical teams. If UHC added or removed codes from the covered list in this update, your charge capture needs to reflect that before the first claim goes out after June 2, 2026.
If you need the current HCPCS Q-code list for skin substitute products or the CPT application codes typically associated with this policy, check UHC's Medicare Advantage coverage policies directly or contact your UHC provider relations representative for the full code appendix.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.